Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR

被引:1
|
作者
Becker, Christian [1 ]
Oecal, Sinan [2 ,3 ]
Nguyen, Hoang D. [2 ,4 ]
Trang Phan [2 ,4 ]
Keul, Marina [1 ]
Simard, Jeffrey R. [2 ,5 ]
Rauh, Daniel [1 ,2 ]
机构
[1] Tech Univ Dortmund, Fak Chem & Chem Biol, Otto Hahn Str 4a, D-44227 Dortmund, Germany
[2] Max Planck Inst Mol Physiol, Chem Genom Ctr, Otto Hahn Str 15, D-44227 Dortmund, Germany
[3] Univ Cologne, Dept Math & Nat Sci, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany
[4] Vietnam Natl Univ Ho Chi Minh City, Univ Sci, 227 Nguyen van Cu Str Dist 5, Ho Chi Minh City, Vietnam
[5] Amgen Inc, 360 Binney St, Cambridge, MA 02142 USA
关键词
GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; INHIBITOR SELECTIVITY; DRUG-RESISTANCE; MUTATIONS; GEFITINIB; DOMAIN; ERLOTINIB; AZD9291; ACTIVATION;
D O I
10.1002/cbic.201600115
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The receptor tyrosine kinase EGFR is regulated by complex conformational changes, and this conformational control is disturbed in certain types of cancer. Many ligands are known to bind EGFR in its active conformation, thereby preventing ATP from binding. Only a few ligands are known to stabilize EGFR in its inactive conformation, thus providing novel strategies for perturbing EGFR activity. We report a direct binding assay that enables the identification of novel ligands that bind to and stabilize the inactive conformation of EGFR.
引用
收藏
页码:990 / 994
页数:5
相关论文
共 50 条
  • [31] Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
    Soucheray, Margaret
    Capelletti, Marzia
    Pulido, Ines
    Kuang, Yanan
    Paweletz, Cloud P.
    Becker, Jeffrey H.
    Kikuchi, Eiki
    Xu, Chunxiao
    Patel, Tarun B.
    Al-Shahrour, Fatima
    Carretero, Julian
    Wong, Kwok-Kin
    Jaenne, Pasi A.
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    CANCER RESEARCH, 2015, 75 (20) : 4372 - 4383
  • [32] EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
    Barnet, Megan B.
    O'Toole, Sandra
    Horvath, Lisa G.
    Selinger, Christina
    Yu, Bing
    Ng, Chiu Chin
    Boyer, Michael
    Cooper, Wendy A.
    Kao, Steven
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 585 - 590
  • [33] EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
    Improta, Giuseppina
    Vita, Giulia
    Tartarone, Alfredo
    Calice, Giovanni
    Omer, Ludmila carmen
    Zupa, Angela
    ANTICANCER RESEARCH, 2025, 45 (01) : 335 - 340
  • [34] Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions
    Chuang, Jody C.
    Salahudeen, Ameen A.
    Wakelee, Heather A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 989 - 993
  • [35] Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
    Tartarone, Alfredo
    Lazzari, Chiara
    Lerose, Rosa
    Conteduca, Vincenza
    Improta, Giuseppina
    Zupa, Angela
    Bulotta, Alessandra
    Aieta, Michele
    Gregorc, Vanesa
    LUNG CANCER, 2013, 81 (03) : 328 - 336
  • [36] Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors
    Wu, Tsung-Che
    Lin, Chia -Chi
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1063 - 1066
  • [37] Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
    Yen, Hsin-Yung
    Liu, Ying-Chih
    Chen, Nai-Yu
    Tsai, Chia-Feng
    Wang, Yi-Ting
    Chen, Yu-Ju
    Hsu, Tsui-Ling
    Yang, Pan-Chyr
    Wong, Chi-Huey
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (22) : 6955 - 6960
  • [38] Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
    Schrock, Alexa B.
    Zhu, Viola W.
    Hsieh, Wen-Son
    Madison, Russell
    Creelan, Benjamin
    Silberberg, Jeffrey
    Costin, Dan
    Bharne, Anjali
    Bonta, Ioana
    Bosemani, Thangavijayan
    Nikolinakos, Petros
    Ross, Jeffrey S.
    Miller, Vincent A.
    Ali, Siraj M.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1312 - 1323
  • [39] EGFR tyrosine kinase inhibitors in squamous cell lung cancer
    Hirsch, Fred R.
    Herbst, Roy S.
    Gandara, David R.
    LANCET ONCOLOGY, 2015, 16 (08) : 872 - 873
  • [40] Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
    Manuel Sepulveda-Sanchez, Juan
    Angeles Vaz, Maria
    Balana, Carmen
    Gil-Gil, Miguel
    Reynes, Gaspar
    Gallego, Oscar
    Martinez-Garcia, Maria
    Vicente, Elena
    Quindos, Maria
    Luque, Raquel
    Ramos, Ana
    Ruano, Yolanda
    Perez-Segura, Pedro
    Benavides, Manuel
    Sanchez-Gomez, Pilar
    Hernandez-Lain, Aurelio
    NEURO-ONCOLOGY, 2017, 19 (11) : 1522 - 1531